Skip to main content
DAE HWA PHARM CO., LTD logo

DAE HWA PHARM CO., LTD — Investor Relations & Filings

Ticker · 067080 ISIN · KR7067080002 KO Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2026-05-28 Director's Dealing
Country KR South Korea
Listing KO 067080

About DAE HWA PHARM CO., LTD

http://www.dhpharm.co.kr

DAE HWA PHARM CO., LTD. is a pharmaceutical company focused on the research, development, and manufacturing of finished drug products. The company's core competency lies in its advanced Drug Delivery System (DDS) technologies, particularly its proprietary lipid-based self-emulsifying platform, DHLASED. This technology enabled the development of Liporaxel®, the world's first approved oral formulation of the anticancer agent paclitaxel. The company's portfolio also includes analgesics and anti-inflammatory drugs, such as the LOXONA trans-dermal patch, as well as aesthetic products like hyaluronic acid fillers and consumer health solutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 88% confidence The document is a mandatory ownership report filed by an officer of the company (a director/executive) detailing his personal share transactions (“장내매수” – on‐market purchases) and resulting securities holdings. This corresponds to insider trading or director dealing filings. It is not an announcement of a corporate report nor a full financial report. Therefore, the correct classification is Director’s Dealing (DIRS).
2026-05-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a mandatory report detailing the ownership status and transaction history of securities held by an officer (임원) and major shareholder. It lists the officer’s name, position, share counts before and after changes, and details of purchase/sale transactions on specific dates. This corresponds to insider/director share transactions reporting. Hence, it is classified under Director’s Dealing (DIRS).
2026-05-28 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence Document is titled “분기보고서” (Quarterly Report) for the period January 1, 2026 – March 31, 2026 (43rd fiscal term). It contains a full set of financial statements, detailed business descriptions, production data, property listings, audit opinions, and notes, not merely an announcement or link to a report. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a regulatory report detailing the share ownership and transaction history of a company director (Kim Eun Seok). It lists holdings, acquisition dates, number of shares before and after, transaction types (e.g., on-market purchases). This matches a Director’s Dealing report (insider trading disclosure) rather than an annual or interim financial report. Therefore, it is classified as DIRS.
2026-05-14 Korean
투자판단관련주요경영사항 (리포락셀액(파클리탁셀)의 품목허가사항 변경허가 승인(유방암 신규 적응증 추가 허가 승인))
Regulatory Filings Classification · 89% confidence The document is a Korean ‘투자판단 관련 주요경영사항’ announcement describing a regulatory approval (MFDS) for a new drug indication. It contains no financial statements or detailed investor materials but is a public regulatory update. This fits the fallback category for general regulatory announcements.
2026-05-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a Korean ‘임원ㆍ주요주주 특정증권등 소유상황보고서’, which is an insider ownership report disclosing an officer’s (Kim Woon Jang) holdings and trades. This matches the “Director’s Dealing” category (insider trades by directors/executives). It is not an announcement of a broader meeting or general regulatory notice, but the actual insider report. Therefore, the correct classification is DIRS.
2026-04-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.